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Abstract
Sterically stabilized liposomes are able to localize at sites of infection and could serve as carriers of antimicrobial agents.
For a rational optimization of liposome localization, the blood clearance kinetics and biodistribution of liposomes differing
in poly(ethylene glycol) (PEG) density, particle size, bilayer fluidity or surface charge were studied in a rat model of a
unilateral pneumonia caused by Klebsiella pneumoniae. It is shown that all liposome preparations studied localize
preferentially in the infected lung compared to the contralateral non-infected lung. A reduction of the PEG density or rise in
particle size resulted in a higher uptake by the mononuclear phagocyte system, lower blood circulation time and lower
infected lung localization. Differences in bilayer fluidity did not affect blood clearance kinetics or localization in the infected
lung. Increasing the amount of negatively charged phospholipids in the liposome bilayer did not affect blood clearance
kinetics, but did reduce localization of this liposome preparation at the site of lung infection. In conclusion, the degree of
localization at the infected site is remarkably independent of the physicochemical characteristics of the PEG liposomes.
Substantial selective liposome localization can be achieved provided that certain criteria regarding PEG density, size and
inclusion of charged phospholipids are met. These properties seem to be a direct consequence of the presence of the polymer
coating operating as a repulsive steric barrier opposing interactions with biological components. ß 1999 Elsevier Science
B.V. All rights reserved.
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1. Introduction
Unfavorable location of an infectious organism,
limited susceptibility to the applied antimicrobial
agent and/or a decreased immune status of the in-
fected host are all major factors complicating the
e⁄cacy of antimicrobial therapy [1^3]. The use of a
drug carrier, like liposomes, could help to improve
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the e⁄cacy of antibiotic treatment by modifying the
pharmacokinetics and tissue distribution of the anti-
biotic. This strategy may increase drug concentra-
tions at the target site and/or reduce toxicity to
non-target tissues enabling higher dosing [4,5].
The location of the infection is an important con-
sideration for the choice of the liposome type to be
used as targeted antibiotic carrier. As intravenously
administered conventional liposomes display a high
a⁄nity for the mononuclear phagocyte system
(MPS), a rapid localization of these liposomes in
MPS-rich organs, most notably in the liver and the
spleen, is observed. This property makes them appro-
priate for the speci¢c targeting of antimicrobials to
infectious organisms residing within MPS cells in
these organs. In addition, since the MPS plays an
important role in the non-speci¢c defense against in-
fections, MPS-directed targeting of liposomal immu-
nomodulators may enhance the non-speci¢c host re-
sistance. Both strategies have been reviewed [6,7].
The limitations of these conventional liposomes as
antibiotic carriers are clear when targeting to infec-
tions outside the MPS is the main goal. Various
strategies have been followed to reduce uptake of
liposomes by the MPS and consequently to increase
their blood residence time, allowing for interaction
with other tissues. At present, coating of the surface
of liposomes with poly(ethylene glycol) (PEG) is a
popular strategy to increase the circulation time of
liposomes. It is thought that the PEG coating pro-
vides a steric barrier against opsonization, thereby
reducing the interaction with the MPS. Conse-
quently, these liposomes, referred to as sterically sta-
bilized liposomes (SSL), exhibit a prolonged circula-
tion time (for reviews see [8^10]).
Previous studies of our group in a model of acute
unilateral pneumonia caused by Klebsiella pneumo-
niae in rats demonstrated that SSL are capable to
substantially localize in the infected left lung. The
presence of a local active infectious process appeared
to be required as minimal liposome localization was
observed in the contralateral non-infected right lung
[11,12]. Furthermore, it was shown that encapsulated
gentamicin was strongly e¡ective in reducing bacte-
rial numbers in the infected left lung as well as pre-
venting mortality, likely due to local release of the
drug from the SSL at the site of infection [13].
The phenomenon of preferential localization of
SSL at pathological sites has also been described
for other in£ammatory conditions like adjuvant ar-
thritis in rats, experimental colitis in rabbits, focal
bacterial infection in the calf muscle of rats and os-
teomyelitis in rabbits [14^17]. However, only little
information is available on the in£uence of liposome
characteristics on the degree of localization of SSL at
in£ammatory foci. Insight into the liposomal proper-
ties favoring the localization in in£ammatory tissue
may help to optimize liposomal formulations for
antimicrobial therapy. The aim of the present study
is to evaluate the e¡ects of PEG surface density,
particle size, bilayer £uidity and surface charge of
SSL on circulation kinetics and localization in in-
fected lung tissue.
2. Materials and methods
2.1. Introduction of a unilateral pneumonia
Speci¢ed pathogen-free female RP/AEur/RijHsd
strain albino rats (18^25 weeks of age, weighing
185^225 g) (Harlan, Horst, The Netherlands) were
used in all experiments. Experiments were approved
by the animal experiments ethical committee of the
Erasmus University Medical Center Rotterdam. A
unilateral pneumonia was induced in the left lung
as described previously [18]. In brief, rats were anes-
thetized by an intramuscular injection of 0.1 ml £ua-
nisone and fentanyl citrate (Hypnorm) (Janssen Ani-
mal Health, Saunderton, UK) followed by an
intraperitoneal injection of 0.3 ml 1:4 v/v diluted
pentobarbital (Nembutal) (Sano¢ Sante¤, Maassluis,
The Netherlands). After incubation followed by can-
nulation of the left primary bronchus, 0.02 ml of a
saline suspension containing 106 K. pneumoniae
(ATCC 43816, capsular serotype 2) was inoculated
in the lower left lung lobe. Bacterial inoculum was
checked by culturing appropriate dilutions of the
bacterial suspension on tryptone soy agar plates
(Unipath, Basingstoke, UK). Following bacterial in-
oculation, rats received an intramuscular injection of
nalorphine bromide to recover from anesthesia (On-
derlinge Pharmaceutische Groothandel, Utrecht, The
Netherlands) and were housed individually with free
access to water and SRMA chow (Hope Farms,
Woerden, The Netherlands).
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2.2. Liposome preparation and characterization
Liposomes were prepared as described previously
[12]. In brief, appropriate amounts of partially hy-
drogenated egg phosphatidylcholine (PHEPC, iodi-
nation value 40) (Asahi Chemical Industry, Ibarakik-
en, Japan), cholesterol (Chol) (Sigma Chemical, St.
Louis, MO, USA), 1,2-distearoyl-sn-glycero-3-phos-
phoethanolamine-N-(PEG-2000) (PEG-DSPE), egg
L-K-phosphatidylcholine (EPC), egg L-K-phosphatid-
ylglycerol (EPG) or distearoyl phosphatidylcholine
(DSPC) (Avanti Polar Lipids, Alabaster, AL, USA)
were dissolved in chloroform:methanol in a round
bottom £ask. The solvent was evaporated under re-
duced pressure in a rotary evaporator and the lipid
mixture was dried under nitrogen for 15 min, redis-
solved in 2-methyl-2-propanol (Sigma Chemical, St.
Louis, MO, USA) and freeze-dried overnight. The
dried lipids were hydrated for 2 h in N-(2-hydroxy
ethyl) piperazine-NP-ethane sulfonic acid (HEPES)/
NaCl bu¡er, pH 7.4 (10 mM HEPES) (Sigma Chem-
ical, St. Louis, MO, USA) and 135 mM NaCl
(Merck, Darmstadt, Germany) containing 5 mM of
the chelator deferoxamine mesylate (Desferal) (No-
vartis, Basel, Switzerland). The chelator was added
to enable labelling with 67Ga (see Section 2.3).
Liposomes of approximately 100 nm (range 80^
120 nm) were obtained by sonication of the hydrated
lipid dispersion for 8 min with an amplitude of 8 W
using a 9.5 mm probe in a MSE Soniprep 150 (Sanyo
Gallenkamp PLC, Leicester, UK). To study the ef-
fect of particle size, liposome populations of three
di¡erent mean sizes (i.e. 100, 280 and 360 nm) were
obtained by multiple extrusion of the hydrated lipid
dispersion through two stacked polycarbonate mem-
branes (Nuclepore, Pleasanton, CA, USA) with pore
sizes of 100 and 100 nm for the 100 nm liposomes,
400 and 200 nm for the 280 nm liposomes and
600 and 400 nm for the 360 nm liposomes.
Particle size distribution was measured using dy-
namic light scattering, detected at an angle of 90‡ to
the laser beam on a Malvern 4700 System (Malvern
Instruments, Malvern, UK). The polydispersity of
the liposome population is reported by the system
as a value between zero and one. A reported value
of one indicates large variations in particle size,
whereas a value of zero indicates a complete mono-
disperse system. For all liposome preparations used
in the experiments, the polydispersity index value
was below 0.3.
The j-potential of 0, 5 or 30 mol% EPG contain-
ing liposomes was measured using a zetasizer
equipped with PCS v1.35 software (Malvern Instru-
ments, Malvern, UK). Liposomes were prepared in
5% aqueous HEPES/NaCl bu¡er and the instrument
was calibrated with electrophoresis standard latex
particles.
2.3. Liposome labelling
To remove non-encapsulated deferoxamine, lipo-
somes were applied on a Sephadex G-50 column
(Pharmacia, Uppsalla, Sweden) and eluted with
HEPES/NaCl bu¡er followed by concentration via
ultracentrifugation at 60 000 rpm for 2 h at 4‡C in
a Beckman ultracentrifuge L-70 (Beckman, Palo
Alto, CA, USA). Liposomes were labelled with
67Ga according to Gabizon et al. [19]. 67Ga-citrate
(1 mCi/ml) (Mallinckrodt Medical, Petten, The Neth-
erlands) was diluted 1:10 in aqueous 5 mg/ml 8-hy-
droxyquinone (Sigma Chemical, St. Louis, MO,
USA) and incubated for 1 h at 52‡C to yield 67Ga-
oxine. 1 ml of this mixture was added per 1000 Wmol
total lipid (TL) of liposomes. Since 67Ga-oxine can
pass the liposomal membrane and has a high a⁄nity
for the encapsulated chelator deferoxamine, the ra-
dioactive label becomes entrapped. 67Ga-deferox-
amine is an appropriate label for monitoring intact
liposomes in the circulation as it is encapsulated in
the liposome interior and it is excreted rapidly via the
kidneys in case it leaks from circulating liposomes
[19]. Free label was removed by gel ¢ltration. Radio-
labelled liposomes were concentrated by ultracen-
trifugation at 60 000 rpm for 2 h at 4‡C in a Beck-
man ultracentrifuge L-70 (Beckman, Palo Alto, CA,
USA). Resulting speci¢c activities were between
4U104 and 2U105 cpm/Wmol TL. The phosphate
concentration was determined colorimetrically ac-
cording to Bartlett [20].
2.4. Blood volume and organ blood content
Total blood volume of the infected rats was 5.3%
of the body weight. This percentage was determined
by labeling syngeneic erythrocytes with 111In-oxine
according to Kurantsin-Mills [21]. Brie£y, in an in-
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dependent experiment, blood samples were taken at
10 min after injection of the labeled erythrocytes as-
suming that all erythrocytes were still present in the
circulation. The dilution factor of the radioactive
111In-label allowed calculation of the total blood vol-
ume as well as the blood content of the various or-
gans.
2.5. Blood circulation kinetics and biodistribution
Experimental groups consisted of six rats. Lipo-
somes were administered intravenous (i.v.) at the se-
lected dose (indicated in the text) via the tail vein at
40 h after bacterial inoculation of the left lung.
Blood samples of approximately 0.3 ml were taken
from alternating groups of three rats by retro-orbital
bleeding using heparinized capillaries at 1, 4, 8,
12 and 16 h after liposome injection. All rats were
bled at 24 h after injection. The blood sample volume
was measured and radioactivity was counted in a
Minaxi autogamma 5000 gamma counter (Packard
Instrument Company, Meriden, CT, USA) allowing
for calculation of the radioactivity present in the
blood (see Section 2.4).
At 24 h after injection, rats were killed by CO2
inhalation and infected left lung, right lung, spleen,
kidneys, liver and heart were dissected. The organs
were weighed and radioactivity was counted to assess
the biodistribution of the liposomes. The contribu-
tion of radioactivity in the blood to the radioactivity
measured in the organs was subtracted (see Section
2.4).
2.6. Statistical analysis
Pharmacokinetic studies have shown that SSL ex-
hibit single ¢rst-order clearance rates independent of
the dose [9,22]. Similarly, in our experiments, the
circulation kinetics of individual animals between
1 and 24 h after injection could be well-described
by a linear relationship on a semi-logarithmic plot
(0.886 r6 1.00).
Data were tested for homogeneity of variance us-
ing Levene’s test. In case of signi¢cant di¡erences in
variance between groups, data were log-transformed.
The paired t-test was used to compare infected left
lung and right lung localization. Comparisons be-
tween groups were made by one-way analysis of var-
iance corrected for multiple comparisons by the Bon-
ferroni method using SPSS for Windows software
release 7.5.2 (Statistical Product and Service Solu-
tions, Chicago, MI, USA).
3. Results
At 40 h after bacterial inoculation of the left lung,
at the time of liposome injection, three zones could
be clearly distinguished in the lobar pneumonia area
in the left lung: the early infected, hemorrhagic and
consolidated zone. Furthermore, limited variation
was noted in severity of infection between animals.
At 40 h after bacterial inoculation, the inoculum of
log 6 bacteria had multiplied to log 9.77 þ 0.24,
whereas the original lung weight of 0.36 þ 0.07 g
had increased to 1.07 þ 0.19 g (mean þ S.D., n = 9).
3.1. E¡ect of PEG density
The circulation kinetics and the biodistribution
pattern of liposomes containing three di¡erent levels
of PEG-DSPE with an approximate molecular
weight of PEG of 2000 (i.e. 1, 5 or 10 mol%) are
shown in Fig. 1A,B, respectively.
The 1 mol% PEG liposomes disappeared from the
C
Fig. 1. E¡ect of PEG density on blood clearance and biodistri-
bution of liposomes. 67Ga-deferoxamine-labelled liposomes were
injected i.v. at 40 h after bacterial inoculation of the left lung
with 106 K. pneumoniae cells at a dose of 75 Wmol TL/kg body
weight. The lipid composition was PHEPC:Chol:PEG-DSPE
1.85:1:0.15 mol:mol for the 5 mol% PEG-DSPE containing
liposome preparation (particle size 104 nm, range 91^115 nm,
n = 8), 1.97:1:0.03 mol:mol for the 1 mol% PEG-DSPE prepa-
ration (particle size 107 nm, range 98^116 nm, n = 2) and
1.7:1:0.3 mol:mol for the 10 mol% PEG-DSPE preparation
(particle size 98 nm, range 96^100 nm, n = 2). (A) Liposome
concentration in nmol TL/ ml blood (left Y-axis) and % of in-
jected dose remaining in the circulation (right Y-axis) at indi-
cated time points after injection. Data were calculated from ra-
dioactivity recovered (n = 3, mean þ S.D.). (B) Biodistribution of
liposomes expressed as nmol TL/organ (left Y-axis) and % of
injected dose/organ (right Y-axis) at 24 h after injection. Data
were calculated from radioactivity recovered (n = 6, mean þ
S.D.). LL = infected left lung, RL = right lung, Spl = spleen,
Li = liver. * = P6 0.05, ** = P6 0.01, *** = P6 0.001. Signi¢cant
di¡erences are noted against the 5 mol% PEG-DSPE containing
preparation.
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bloodstream faster as compared to the 5 and 10
mol% PEG liposomes (P6 0.01) (Fig. 1A). An in-
crease of the PEG content from 5 up to 10 mol%
did not a¡ect the circulation kinetics. The biodistri-
bution data show that, for all three PEG liposome
preparations, the localization in the infected left lung
at 24 h after injection was approximately 3^4-fold
higher than the corresponding localization in the un-
infected right lung (P6 0.001) (Fig. 1B). Yet, the
degree of localization in the infected left lung of
the 1 mol% PEG liposomes was somewhat lower
( þ 20%) compared to the 5 mol% PEG liposomes
(P6 0.05), while the extent of localization of the
5 and 10 mol% PEG liposomes in the infected lung
was similar. The hepatosplenic uptake of the 1 mol%
PEG liposomes was signi¢cantly higher than the
5 and 10 mol% PEG liposomes (P6 0.05 and
P6 0.005, respectively). The latter two liposome
types displayed a similar degree of localization in
the liver and spleen. Localization in the uninfected
right lung was not signi¢cantly di¡erent for the three
di¡erent liposome preparations. Very low levels of
liposome localization were seen in heart (6 40
Fig. 2. E¡ect of particle size on blood clearance and biodistri-
bution of liposomes. See Fig. 1 for details. The lipid composi-
tion of the liposomes was PHEPC:Chol:PEG-DSPE
1.85:1:0.15 mol:mol. 100 nm formulation particle size: 104 nm,
range 91^115 nm, n = 8; 280 nm formulation particle size: 277
nm, range 268^286 nm, n = 2; 360 nm formulation particle size:
359 nm, range 331^387 nm, n = 2. Signi¢cant di¡erences against
the 100 nm-sized liposome preparation are noted.
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nmol TL) and kidneys (6 200 nmol TL) (data not
shown).
3.2. E¡ect of particle size
The circulation kinetics and the biodistribution
pattern of liposomes di¡ering in mean size (i.e. 100,
280 and 360 nm) are shown in Fig. 2A,B, respec-
tively. PEG liposomes with a mean size of 100 nm
were removed from the bloodstream at a much lower
rate as compared to the 280 and 360 nm liposome
formulations (P6 0.01 and P6 0.05, respectively)
(Fig. 2A). Regarding the biodistribution pattern, it
was observed that the localization in the uninfected
right lung and the infected left lung was approxi-
mately 2-fold lower in case of the 280 and 360 nm
liposome preparations compared to the 100 nm PEG
liposomes (P6 0.001) (Fig. 2B). Importantly, for
each liposome formulation, the localization in the
infected left lung was approximately 4-fold higher
than in the uninfected right lung (P6 0.001). Splenic
uptake appeared to increase considerably with an
increasing size of the PEG liposomes (P6 0.001).
The distribution to liver, heart (data not shown)
and kidneys (data not shown) was not signi¢cantly
di¡erent for any of the liposome preparations in this
experiment.
3.3. E¡ect of bilayer £uidity
Bilayer £uidity is determined by the lipid compo-
sition of the liposome. Hydrogenated phospholipids
yield rigid bilayers whereas more unsaturated phos-
pholipids give bilayers a more £uid character [23].
Besides, Chol has also been shown to be an impor-
tant modulator of bilayer £uidity by increasing bi-
layer rigidity and lateral packing [23]. The liposome
preparations evaluated here vary, regarding bilayer
£uidity, as follows (in order of increasing £uidity):
DSPC:PEG-DSPE, PHEPC:PEG-DSPE, EPC:
PEG-DSPE. One liposome preparation contains ad-
ditionally Chol (i.e. PHEPC:Chol:PEG-DSPE) to
examine the e¡ect of inclusion of the steroid. The
circulation kinetics and the biodistribution pattern
of liposomes di¡ering in bilayer £uidity are shown
in Fig. 3A,B, respectively. The circulation times of all
four liposome preparations evaluated were similar
(Fig. 3A). Regarding the biodistribution pro¢le, all
four liposome formulations showed an approxi-
mately 4-fold higher localization in the infected left
lung compared to the uninfected right lung
(P6 0.001) (Fig. 3B). Tissue distribution patterns
of the various liposome formulations were not sig-
ni¢cantly di¡erent.
Fig. 3. E¡ect of bilayer £uidity on blood clearance and biodis-
tribution of liposomes. See Fig. 1 for details. The lipid compo-
sition of the PHEPC:Chol:PEG-DSPE liposome was
1.85:1:0.15 mol:mol (particle size 104 nm, range 91^115 nm,
n = 8), of the DSPC:PEG-DSPE 1.9:0.1 mol:mol (particle size
114 nm, range 95^133 nm, n = 2), of the PHEPC:PEG-DSPE
1.9:0.1 mol:mol (particle size 121 nm, range 109^133 nm, n = 2)
and of the EPC:PEG-DSPE preparation 1.9:0.1 mol:mol (par-
ticle size 84 nm, range 76^92 nm, n = 2).
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3.4. E¡ect of charged phospholipids
The circulation kinetics and the biodistribution
pattern of PEG liposomes di¡ering in EPG content
(i.e. 0, 5 and 30 mol%) were determined to study the
e¡ect of charged phospholipids (Fig. 4A,B). The j-
potentials of the 0, 5 and 30 mol% EPG containing
liposomes were measured. The j-potential decreased
slightly with an increasing EPG content, under the
experimental conditions used, from 310.7 þ 1.1 mV
for the 0 mol% EPG containing liposomes via
313.4 þ 1.4 mV for the 5 mol% EPG preparation
to 319.7 þ 1.1 mV for the 30 mol% EPG containing
liposomes (mean þ S.D., n = 3 preparations).
Inclusion of the negatively charged phospholipid
did not appear to in£uence the circulation character-
istics of the PEG liposomes (Fig. 4A). The degree of
localization in the infected lung was not a¡ected by
the inclusion of 5 mol% EPG. Remarkably, inclusion
of 30 mol% EPG resulted in an approximately 2-fold
reduced target localization compared to the PEG lip-
osomes containing 0 and 5 mol% EPG (P6 0.01)
(Fig. 4B). But, for all three types of PEG liposomes
di¡ering in EPG content, the degree of localization
in the infected left lung was higher than in the unin-
fected right lung (P6 0.01). The 30 mol% EPG con-
taining preparation showed a signi¢cantly increased
splenic localization (P6 0.01) compared to the 0 and
5 mol% EPG containing PEG liposomes. Distribu-
tion of the three PEG liposome types to liver, kid-
neys and heart was not signi¢cantly di¡erent (heart
and kidney data not shown). Total accumulation
within the infected left lung, right lung, liver and
spleen was not signi¢cantly di¡erent between the lip-
osome formulations di¡ering in EPG content.
(4572 þ 623, 4655 þ 855, 5406 þ 618 nmol TL/tissues
for the 0, 5 and 30 mol% EPG containing liposomes,
respectively, mean þ S.D., n = 6).
4. Discussion
SSL, obtained by coating the liposome surface
with PEG via inclusion of PEG-DSPE into the lipo-
somes, display a considerably increased circulation
time compared to conventional liposomes lacking
the PEG coating [9,10,22,24]. This long-circulating
property has been exploited to reach infectious sites
localized outside the major MPS organs, the liver
and spleen [14^17]. SSL-encapsulated gentamicin
showed a superior therapeutic e¡ect compared to
the free drug in our rat model of acute unilateral
pneumonia in the left lung caused by K. pneumoniae
[13]. SSL are, therefore, attractive candidates for site-
selective drug delivery of antimicrobial agents. In
Fig. 4. E¡ect of the EPG level on blood clearance and biodis-
tribution of liposomes. See Fig. 1 for details. The lipid compo-
sition was PHEPC:Chol:PEG-DSPE:EPG 1.85:1:0.15:0 mol:
mol for the 0 mol% EPG containing liposome preparation (par-
ticle size 104 nm, range 91^115 nm, n = 8), 1.7:1:0.15:0.15
mol:mol for the 5 mol % EPG preparation (particle size 93
nm, range 87^99 nm, n = 2) and 0.95:1:0.15:0.9 mol:mol for
the 30 mol% EPG preparation (particle size 82 nm, range 78^
86 nm, n = 2). Signi¢cant di¡erences against the 0 mol% EPG
containing liposome preparation are noted.
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order to be able to rationally optimize liposomal
preparations for targeted drug delivery to non-MPS
infectious foci, it is important to gain insight into the
liposome characteristics potentially a¡ecting the
process of liposome localization at the infected site.
In this study, the e¡ects of PEG density, liposomal
size, bilayer £uidity and charge on circulation
kinetics and biodistribution of liposomes were eval-
uated in our rat pneumonia model.
Liposomes containing 1 mol% PEG displayed in-
ferior localization at the infected site and a shorter
circulation time compared to liposomes containing
5 or 10 mol% PEG. It has been shown previously
in healthy animals that inclusion of 5^7.5 mol%
PEG-DSPE is optimal for achieving maximal prolon-
gation of the circulation time, in case of PEG with
an approximate molecular weight of 2000 [24]. This
¢nding is consistent with the present observations in
a rat model of bacterial infection, showing a lack of
e¡ect of increasing the PEG density from 5 to 10
mol% on blood circulation time and tissue disposi-
tion (Fig. 1A,B). Inclusion of 1 mol% PEG-DSPE is,
apparently, less e⁄cient in prolonging the circulation
time as compared to inclusion of 5 or 10 mol% PEG-
DSPE. The lower localization in the infected left lung
of the 1 mol% PEG-DSPE SSL is most likely related
to the faster removal from the bloodstream, resulting
in a reduced possibility to interact with the target
site. However, it cannot be totally excluded that
PEG has a direct e¡ect as well. It has been shown
in tumor bearing mice that PEG-coated liposomes
have an intrinsically higher tumor vascular perme-
ability coe⁄cient than conventional liposomes [25].
In this view, the presence of 1 mol% PEG-DSPE
may have resulted in a suboptimal PEG density to
facilitate extravasation. Future experiments will fo-
cus on the relative importance of the circulation
time versus the presence of a PEG coating.
A positive correlation between circulation times
and infected lung localization is also apparent from
the experiments on the e¡ect of particle size on cir-
culation kinetics and biodistribution of SSL. SSL
with mean particle sizes of 280 or 360 nm show an
approximately 2-fold lower target localization com-
pared to the 100 nm PEG liposomes. Again, this may
be related to di¡erences in circulation times as 100
nm SSL are cleared more slowly from the blood-
stream compared to the SSL with larger mean sizes.
On the other hand, the reduced localization at the
site of infection of the two liposome types with the
larger mean size may also be a direct consequence of
the particle size of the liposomes, which may have
been too large to achieve equally e⁄cient extravasa-
tion compared to the 100 nm PEG liposome prepa-
ration. Boerman and co-workers studied the e¡ect of
particle size of SSL on liposome localization in a
focal infection in the calf muscle of rats. The studied
particle sizes were between 90 and 220 nm. Their
study showed that particle sizes, within this range,
do not a¡ect the degree of target localization [26].
On the basis of the present results, we speculate that
a further increase of the particle size to sizes well
above 220 nm is required to observe a signi¢cant
reduction in localization at the site of infection.
The higher splenic uptake of the larger PEG-coated
liposomes, noticed in this study, has also been ob-
served by Litzinger and colleagues for SSL of ap-
proximately 300 nm and was suggested to be due
to a ¢ltration e¡ect within the splenic collagen ¢ber
meshwork [27]. Although the infected lung localiza-
tion of the two larger SSL is relatively low, it can
nonetheless be argued that these liposomes are still
attractive for the delivery of antimicrobials. The
present results demonstrate that SSL with a mean
particle size up to 360 nm are still able to localize
preferentially in infected tissue, though less e⁄cient
in this regard than the 100 nm SSL. If the liposome-
associated drug load is increased su⁄ciently for the
larger liposomes, it can be envisaged that the net
drug concentration at the target site may even be
increased when larger SSL with suboptimal localiza-
tion characteristics are used.
Since bilayer £uidity can be an important determi-
nant of the release of liposome-encapsulated com-
pounds, this liposome characteristic should also be
considered regarding its e¡ect on SSL localization at
the site of infection. Generally, it is reported that
release of encapsulated compounds increases with
an increasing £uidity of the liposome bilayer, which
has also been shown to a¡ect the therapeutic e⁄cacy
[28^32]. Minimal variations were noticed in circula-
tion kinetics and tissue distribution of the liposome
formulations di¡ering in bilayer £uidity. This ¢nding
is in agreement with previous results reported by
Woodle et al. [10,33]. Apparently, bilayer £uidity of
SSL may be chosen to optimize drug retention in the
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blood stream and release pro¢le at the site of infec-
tion without compromising target localization.
The only factor that appeared to adversely a¡ect
target site localization without compromising circu-
lation kinetics was incorporation of 30 mol% EPG
into the SSL formulation. Charged phospholipids are
often added to a liposomal preparation to improve
drug loading and/or stability of the formulation
against aggregation during storage. The PEG coating
has a distinct e¡ect on the liposomal surface charge.
The PEG coating moves the hydrodynamic plane of
shear from the charged surface of the liposome to the
edge of the PEG coating. The j-potential measure-
ments as well as Gouy-Chapman calculations on the
0, 5 and 30 mol% EPG containing PEG liposomes
suggested that in physiological ionic strength, the j-
potential of the 30 mol% EPG SSL would be negli-
gible at 2^3 nm from the surface, as the Debye length
in this milieu is only 0.8 nm. Estimates for the thick-
ness of the PEG coating, for PEG with a molecular
weight of 2000, range from 3 to 5 nm [34,35]. There-
fore, inclusion of EPG was not expected to have an
e¡ect on the circulation kinetics or biodistribution of
SSL. However, the biodistribution pro¢le of the 30
mol% EPG containing preparation shows an approx-
imately 2-fold lower target localization compared to
the 0 and 5 mol% EPG containing liposomes, but
similar circulation kinetics as the 0 and 5 mol%
EPG containing liposomes. It is speculated that the
inclusion of 30 mol% EPG may have conferred a
small but detectable negative j-potential at the edge
of the PEG coating, allowing for interaction with
biological components.
The results of the present study are to a certain
degree in accordance with studies on pharmaco-
kinetics and target localization of SSL in experimen-
tal tumor models. With respect to tumor localization
of SSL, it is generally accepted that prolongation of
the liposomal circulation time is bene¢cial for target
localization [5,8^10,25,27,36]. The results regarding
the e¡ect of the PEG density, particle size and bi-
layer £uidity in the present study as well as previous
results point in the same direction [12]. It has been
demonstrated that tumor localization of SSL is a
result of the increased microvascular permeability
in malignant tissue [9,25]. As increased capillary per-
meability is also one of the hall marks of in£amed
tissue, we suggest that selective SSL localization in
infected tissue is a result of a similar e¡ect of micro-
vascular permeability changes.
In conclusion, SSL o¡er interesting possibilities for
delivery of antibiotics to sites of bacterial infection
localized outside the major MPS organs. It is shown
here that the degree of localization at the infected site
is remarkably independent of the physicochemical
characteristics of the PEG liposomes. Substantial se-
lective liposome localization can be achieved pro-
vided that certain criteria regarding PEG density,
size and inclusion of charged phospholipids are
met. In view of the di¡erences in pharmacodynamics
of the di¡erent classes of antibiotics, the rate and
extent of release of encapsulated antibiotic from the
PEG liposome extravasated into the infected site is
an important issue. The present ¢ndings indicate that
manipulation of the release pro¢le by variation of
the lipid composition may be possible without com-
promising the prolonged circulation and target local-
ization properties. These properties seem to be a di-
rect consequence of the presence of the polymer
coating operating as a repulsive steric barrier oppos-
ing interactions with biological components.
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